Session

IBD: Drug monitoring

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

DEFINITION OF A BACTERIAL SIGNATURE AS A PREDICTOR OF ANTI TNF TREATMENT RESPONSE
DEFINITION OF A BACTERIAL SIGNATURE AS A PREDICTOR OF ANTI TNF TREATMENT RESPONSE

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL
ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

DEFINITION OF A BACTERIAL SIGNATURE AS A PREDICTOR OF ANTI TNF TREATMENT RESPONSE
DEFINITION OF A BACTERIAL SIGNATURE AS A PREDICTOR OF ANTI TNF TREATMENT RESPONSE

IBD: Drug monitoring  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

IBD: Drug monitoring  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

IBD: Drug monitoring  et al.

ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL
ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL

IBD: Drug monitoring  et al.

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

IBD: Drug monitoring  et al.

Item 1 - 10 / 10
1